COVID-19 Vaccines Authorized in the United States |
|
Pfizer-BioNTech |
Moderna |
Janssen (J&J) |
Vaccine type |
mRNA |
mRNA |
viral vector |
Authorized age groups |
5 – 11 years |
≥12 years |
≥ 18 years |
≥ 18 years |
Number of doses in initial series |
2 |
2 |
2 |
1 |
Interval between doses in initial series |
21 days |
21 days |
28 days |
n/a |
Dose volume |
0.2 mL pediatric formula |
0.3 mL |
0.5 mL |
0.5 mL |
FDA status |
Emergency Use Authorization |
Approved |
Emergency Use Authorization |
Emergency Use Authorization |
|
|
|
|
|
|
|
|
|
|
Individuals may receive influenza and any other vaccines at the same time as a COVID-19 vaccine. |
|
|
|
|
|
|
|
|
|
|
|
Pfizer-BioNTech |
Moderna |
Janssen (J&J) |
Authorized booster |
yes |
yes |
yes |
Interval between initial series and booster |
6 months |
6 months |
2 months |
Dose volume |
0.3 mL |
0.25 mL |
0.5 |
Individuals qualifying for booster |
≥ 16 years old |
≥ 18 years old |
≥ 18 years old |
FDA status |
Emergency Use Authorization |
Emergency Use Authorization |
Emergency Use Authorization |
Heterologous (or "mix and match") booster doses are allowed following the eligibility requirements of the individual’s primary COVID-19 vaccine. |
|
|
|
|
|
|
|
|
|
|
|
Pfizer-BioNTech |
Moderna |
Janssen (J&J) |
Authorized 3rd dose |
yes |
yes |
n/a |
Interval between initial series and 3rd dose |
28 days |
28 days |
n/a |
Dose volume |
0.3 mL |
0.5 mL |
n/a |
Individuals qualifying for 3rd dose |
≥12 years |
≥ 18 years |
n/a |
|
Moderate or severely immunocompromised individuals: |
Moderate or severely immunosuppressed individuals: |
n/a |
|
Receiving active cancer treatment for tumors or cancers of the blood |
Receiving active cancer treatment for tumors or cancers of the blood |
|
|
Received an organ transplant and are taking medicine to suppress the immune system |
Received an organ transplant and are taking medicine to suppress the immune system |
|
|
Received a stem cell transplant within the last two years or are taking medicine to suppress the immune system |
Received a stem cell transplant within the last two years or are taking medicine to suppress the immune system |
|
|
Have moderate or severe primary immunodeficiency (such as DiGeorge syndrome or Wiskott-Aldrich syndrome) |
Have moderate or severe primary immunodeficiency (such as DiGeorge syndrome or Wiskott-Aldrich syndrome) |
|
|
Have advanced HIV infection (high viral load or low CD4 count)or untreated HIV infection |
Have advanced HIV infection (high viral load or low CD4 count)or untreated HIV infection |
|
|
Active treatment with high-dose corticosteroids or other drugs that may suppress immune response |
Active treatment with high-dose corticosteroids or other drugs that may suppress immune response |
|
FDA status |
Emergency Use Authorization |
Emergency Use Authorization |
n/a |
Additional 3rd doses should be the same vaccine type as the individual’s primary COVID-19 vaccine if available. |